In 241 patients with BCLC stage B unresectable hepatocellular carcinoma, TACE plus radiofrequency ablation vs TACE alone lengthened median PFS (17.7 vs 7.3 months; HR 0.47) and median OS (88.6 vs 35.1 months; HR 0.50). Grade 3–4 treatment-related adverse events: 23.2% vs 18.3%.
RCTn = 241
Lyu et al. Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial